Pembrolizumab and Olaparib in Cervical Cancer Patients
Status:
Recruiting
Trial end date:
2031-11-01
Target enrollment:
Participant gender:
Summary
The study is a non-randomized, open-label phase II clinical trial to test the investigational
combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with
advanced or recurrent cervical carcinoma after standard chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Baptist Health South Florida
Collaborators:
Florida Department of Health Merck Sharp & Dohme Corp.